Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Galectin-8 induces partial epithelial-mesenchymal transition with invasive tumorigenic capabilities involving a FAK/EGFR/proteasome pathway in Madin-Darby canine kidney cells.
Oyanadel C, Holmes C, Pardo E, Retamal C, Shaughnessy R, Smith P, Cortés P, Bravo-Zehnder M, Metz C, Feuerhake T, Romero D 5th, Roa JC, Montecinos V, Soza A, González A. Oyanadel C, et al. Among authors: cortes p. Mol Biol Cell. 2018 Mar 1;29(5):557-574. doi: 10.1091/mbc.E16-05-0301. Epub 2018 Jan 3. Mol Biol Cell. 2018. PMID: 29298841 Free PMC article.
Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.
Pardo E, Cárcamo C, Uribe-San Martín R, Ciampi E, Segovia-Miranda F, Curkovic-Peña C, Montecino F, Holmes C, Tichauer JE, Acuña E, Osorio-Barrios F, Castro M, Cortes P, Oyanadel C, Valenzuela DM, Pacheco R, Naves R, Soza A, González A. Pardo E, et al. Among authors: cortes p. PLoS One. 2017 Jun 26;12(6):e0177472. doi: 10.1371/journal.pone.0177472. eCollection 2017. PLoS One. 2017. PMID: 28650992 Free PMC article.
The Wnt-dependent master regulator NKX1-2 controls mouse pre-implantation development.
Nakagawa S, Carnevali D, Tan X, Alvarez MJ, Parfitt DE, Di Vicino U, Arumugam K, Shin W, Aranda S, Normanno D, Sebastian-Perez R, Cannatá C, Cortes P, Neguembor MV, Shen MM, Califano A, Cosma MP. Nakagawa S, et al. Among authors: cortes p. Stem Cell Reports. 2024 May 14;19(5):689-709. doi: 10.1016/j.stemcr.2024.04.004. Epub 2024 May 2. Stem Cell Reports. 2024. PMID: 38701778
Nano/microformulations for Bacteriophage Delivery.
Cortés P, Cano-Sarabia M, Colom J, Otero J, Maspoch D, Llagostera M. Cortés P, et al. Methods Mol Biol. 2024;2734:117-130. doi: 10.1007/978-1-0716-3523-0_7. Methods Mol Biol. 2024. PMID: 38066365
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
342 results